congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Other/Multi
ASCO QCS 2024 | September 27-28, 2024
Health-related quality of life of Canadian patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer
Poster
Other/Multi
ASCO QCS 2024 | September 27-28, 2024
Real-world clinical outcomes among non-squamous advanced non-small cell lung cancer (aNSCLC) patients treated with docetaxel-based regimens post initial standard of care (SOC) in the United States
Poster
HER3-DXd
ASCO QCS 2024 | September 27-28, 2024
Real-world outcomes among advanced EGFRm NSCLC patients after osimertinib and platinum-based chemotherapy: An update to a natural history study with an extended data set
Poster
Other/Multi
ASCO QCS 2024 | September 27-28, 2024
Survival outcomes of Black/African American patients with HER2-negative, advanced breast cancer across three academic cancer centers in the United States
Poster
Other/Multi
ASCO QCS 2024 | September 27-28, 2024
Treatment patterns and clinical outcomes in HER2-low metastatic breast cancer, 2018–2023: A retrospective observational study